Fulranumab in Patients With Pain Associated With Postherpetic Neuralgia and Postraumatic Neuropathy: Efficacy, Safety, and Tolerability Results From a Randomized, Double-blind, Placebo-controlled, Phase-2 Study

OBJECTIVE: Fulranumab is an antibody that specifically neutralizes the biological activity of human nerve growth factor. This multicenter, phase-2, randomized, double-blind (DB), placebo-controlled study evaluated the analgesic efficacy and safety of fulranumab in postherpetic neuralgia (PHN) and po...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hao, Romano, Gary, Fedgchin, Margaret, Russell, Lucille, Sanga, Panna, Kelly, Kathleen M., Frustaci, Mary Ellen, Thipphawong, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5228615/
https://www.ncbi.nlm.nih.gov/pubmed/27153360
http://dx.doi.org/10.1097/AJP.0000000000000388

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5228615/
https://www.ncbi.nlm.nih.gov/pubmed/27153360
http://dx.doi.org/10.1097/AJP.0000000000000388

Ejemplares similares